Checkpoint Therapeutics (CKPT) Lowered to “Hold” at Zacks Investment Research

Checkpoint Therapeutics (NASDAQ:CKPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

Separately, HC Wainwright started coverage on Checkpoint Therapeutics in a research note on Friday, December 8th. They issued a “buy” rating and a $11.00 price target on the stock.

Shares of Checkpoint Therapeutics (NASDAQ:CKPT) traded down $0.25 on Wednesday, reaching $3.61. The company had a trading volume of 155,200 shares, compared to its average volume of 86,350. The stock has a market cap of $92.08 and a PE ratio of -3.22. Checkpoint Therapeutics has a 1 year low of $3.35 and a 1 year high of $15.00.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/03/checkpoint-therapeutics-ckpt-lowered-to-hold-at-zacks-investment-research.html.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply